Abstract:Persistent pulmonary hypertension of the newborn (PPHN) is the most common neonatal form and mostly reversible after a few days with improvement of the underlying pulmonary condition. When pulmonary hypertension (PH) persists despite adequate treatment, the severity of parenchymal lung disease should be assessed by chest CT. Pulmonary vein stenosis may need to be ruled out by cardiac catheterisation and lung biopsy, and genetic workup is necessary when alveolar capillary dysplasia is suspected. In PPHN, optimisation of the cardiopulmonary situation including surfactant therapy should aim for preductal SpO2between 91% and 95% and severe cases without post-tricuspid-unrestrictive shunt may receive prostaglandin E1 to maintain ductal patency in right heart failure. Inhaled nitric oxide is indicated in mechanically ventilated infants to reduce the need for extracorporal membrane oxygenation (ECMO), and sildenafil can be considered when this therapy is not available. ECMO may be indicated according to the ELSO guidelines. In older preterm infant, where PH is mainly associated with bronchopulmonary dysplasia (BPD) or in term infants with developmental lung anomalies such as congenital diaphragmatic hernia or cardiac anomalies, left ventricular diastolic dysfunction/left atrial hypertension or pulmonary vein stenosis, can add to the complexity of the disease. Here, oral or intravenous sildenafil should be considered for PH treatment in BPD, the latter for critically ill patients. Furthermore, prostanoids, mineralcorticoid receptor antagonists, and diuretics can be beneficial. Infants with proven or suspected PH should receive close follow-up, including preductal/postductal SpO2measurements, echocardiography and laboratory work-up including NT-proBNP, guided by clinical improvement or lack thereof.

Pulmonary Hypertension in Developmental Lung Diseases

The Progress in the Treatment of Persistent Pulmonary Hypertension in Neonatal

Clinical Features and Prognosis of Bronchopulmonary Dysplasia Complicated by Pulmonary Hypertension in Preterm Infants

Diagnosis and treatment of pulmonary hypertension in infancy

Epigenetic Modulation in the Initiation and Progression of Pulmonary Hypertension.

An interdisciplinary consensus approach to pulmonary hypertension in developmental lung disease

Pathophysiology of persistent pulmonary hypertension of the newborn: Impact of the perinatal environment

Navigating Diagnostic and Treatment Challenges of Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia

Pulmonary hypertension in the newborn- etiology and pathogenesis

Advances in the Diagnosis and Management of Persistent Pulmonary Hypertension of the Newborn

Pathophysiology and Management of Persistent Pulmonary Hypertension of the Newborn

Pulmonary hypertension associated with bronchopulmonary dysplasia in preterm infants

Pulmonary hypertension associated with acute or chronic lung diseases in the preterm and term neonate and infant. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK

Pulmonary Hypertension: The Hidden Danger for Newborns

Pathophysiologic mechanisms of persistent pulmonary hypertension of the newborn

Advances in Neonatal Pulmonary Hypertension

The Practical Challenges of Diagnosis and Treatment Options in Persistent Pulmonary Hypertension of the Newborn: A Developing Country's Perspective

Neonatal and Postneonatal Pulmonary Hypertension

Etiology, Diagnosis and Management of Persistent Pulmonary Hypertension of the Newborn in Resource-limited Settings

Diagnosis and management of pulmonary hypertension in infants with bronchopulmonary dysplasia